文献速递乳腺癌

HER2阳性乳腺癌管理:不断演变的标准与新的挑战

Evolving standards of care and new challenges in the management of HER2-positive breast cancer.
PubMed 文献 · CA Cancer J Clin · 2020-08-19

本文综述HER2阳性乳腺癌近20年治疗进展,FDA已批准7种HER2靶向药物用于早期和/或晚期疾病。尽管肿瘤结局持续改善,晚期患者多因原发或获得性耐药死亡,早期术前系统治疗后残留浸润性疾病者远处复发和死亡风险更高。治疗降阶与升阶概念对个体化治疗日益重要,本文讨论(新)辅助和转移 setting 的标准更新及新挑战。

要点

  • FDA已批准7种HER2靶向治疗用于早期和/或晚期HER2阳性乳腺癌。
  • 晚期患者多因原发或获得性耐药死亡;早期术前治疗后残留浸润性疾病者远处复发和死亡风险更高。
  • 治疗降阶与升阶是当前个体化治疗的主要焦点。

核心结论

  • HER2阳性乳腺癌管理快速演变,肿瘤结局持续改善,但耐药和早期残留 disease 高风险仍是核心挑战。

研究设计与样本

  • 综述,讨论(新)辅助和转移 setting 的标准更新、新联合治疗及管理挑战。

主要发现

  • FDA已批准7种HER2靶向治疗用于早期和/或晚期HER2阳性乳腺癌。
  • 晚期HER2阳性乳腺癌患者多因原发或获得性耐药死亡。
  • 早期HER2阳性乳腺癌术前系统治疗后残留浸润性疾病者远处复发和死亡风险更高。

临床怎么用

  • 治疗降阶与升阶概念用于优化个体化治疗。
  • 关注(新)辅助和转移 setting 的标准更新及新型联合治疗。
  • 需应对原发与获得性耐药、预测生物标志物识别、影像技术整合及HER2阳性脑转移治疗等挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The management of human epidermal growth factor receptor (HER2)-positive breast cancer (BC) has rapidly evolved over the last 20 years. Major advances have led to US Food and Drug Administration approval of 7 HER2-targeted therapies for the treatment of early-stage and/or advanced-stage disease. Although oncologic outcomes continue to improve, most patients with advanced HER2-positive BC ultimately die of their disease because of primary or acquired resistance to therapy, and patients with HER2-positive early BC who have residual invasive disease after preoperative systemic therapy are at a higher risk of distant recurrence and death. The concept of treatment de-escalation and escalation is increasingly important to optimally tailor therapy for patients with HER2-positive BC and is a major focus of the current review. Research efforts in this regard are discussed as well as updates regarding the evolving standard of care in the (neo)adjuvant and metastatic settings, including the use of novel combination therapies. The authors also briefly discuss ongoing challenges in the management of HER2-positive BC (eg, intrinsic vs acquired drug resistance, the identification of predictive biomarkers, the integration of imaging techniques to guide clinical practice), and the treatment of HER2-positive brain metastases. Research aimed at superseding these challenges will be imperative to ensure continued progress in the management of HER2-positive BC going forward.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Choong GM, Cullen GD, O'Sullivan CC, et al. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J Clin. 2020. PMID: 32813307. doi:10.3322/caac.21634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。